Lisata Therapeutics, Inc. (LSTA)

Market Cap	19.76M
Revenue (ttm)	1,000,000
Net Income (ttm)	-19.99M
Shares Out	8.41M
EPS (ttm)	-2.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,955
Open	2.386
Previous Close	2.410
Day's Range	2.350 - 2.400
52-Week Range	2.050 - 4.200
Beta	1.16
Analysts	Strong Buy
Price Target	15.00 (+538.3%)
Earnings Date	May 8, 2025

About LSTA

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is in Phase 2 clinical studies for the treatment of solid tumor, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, colon cancer and glioblastoma multiforme, in combination with a range of anti-cancer regimens. Lisata Therapeutics, Inc. was incorporated in 1980 and is h...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1980
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: LSTA
• Website: https://www.lisata.com

Analyst Forecast

According to one analyst, the rating for LSTA stock is "Strong Buy" and the 12-month stock price forecast is $15.0.

Price Target

$15.0

(538.30% upside)

Analyst Consensus: Strong Buy